Skip to main content
. 2020 Oct 23;22(12):669–700. doi: 10.1021/acscombsci.0c00099

Figure 6.

Figure 6

Co-delivery of docetaxel–siRNA in treatment of cancer. Suppression of the proliferation and metastasis of cancer cells is provided using siRNA-ATG7, p65, MMP-9, and MAPK. This results in increase in cytotoxicity of DTX docetaxel against cancer cells. Nanoparticles provide a platform for co-delivery of docetaxel and siRNA in triggering chemosensitivity.